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ABSTRACT
PRKCα: IDENTIFICATION OF A NOVEL DOWNSTREAM TARGET OF WT1
Publication No._____________
Devin Jacob Jones, M.S.
Supervisory Professor: Vicki Huff, Ph.D.
Wilms tumor is a childhood tumor of the kidney arising from the undifferentiated
metanephric mesenchyme. Tumorigenesis is attributed to a number of genetic and
epigenetic alterations. In 20% of Wilms tumors, Wilms tumor gene 1 (WT1) undergoes
inactivating homozygous mutations causing loss of function of the zinc finger
transcription factor it encodes. It is hypothesized that mutations in WT1 result in
dysregulation of downstream target genes, leading to aberrant kidney development
and/or Wilms tumor. These downstream target genes are largely unknown, and
identification is important for further understanding Wilms tumor development.
Heatmap data of human Wilms tumor protein expression, generated by reverse phase
protein assay analysis (RPPA), show significant correlation between WT1 mutation
status and low PRKCα expression (p= 0.00013); additionally, p-PRKCα (S657) also
shows decreased expression in these samples (p= 0.00373). These data suggest that the
WT1 transcription factor regulates PRKCα expression, and that PRKCα plays a potential
role in Wilms tumor tumorigenesis. We hypothesize that the WT1 transcription factor
directly/indirectly regulates PRKCα and mutations occurring in WT1 lead to decreased
expression of PRKCα. Prkcα and Wt1 have been shown to co-localize in E14.5
mesenchymal cells of the developing kidney. siRNA knockdown, in-vivo ablation, and
tet-inducible expression of Wt1 each independently confirm regulation of Prkcα
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expression by Wt1 at both RNA and protein levels, and investigation into possible WT1
binding sites in PRKCα regulatory regions has identified multiple sites to be confirmed
by luciferase reporter constructs. With the goal of identifying WT1 and PRKCα
downstream targets, RPPA analysis of protein expression in mesenchymal cell culture,
following lentiviral delivered shRNA knockdown of Wt1 and shRNA knockdown of
Prkcα, will be carried out.
Apart from Wilms tumor, WT1 also plays an important role in Acute Myeloid
Leukemia (AML). WT1 mutation status has been implicated, controversially, as an
independent poor-prognosis factor in leukemia, leading to decreased probability of
overall survival, complete remission, and disease free survival. RPPA analysis of AML
patient samples showed significant decreases in PRKCα/p-PRKCα protein expression in
a subset of patients (Kornblau, personal communication); therefore, the possible role of
WT1 and PRKCα in leukemia disease progression is an additional focus of this study.
WT1 mutation analysis of diploid leukemia patient samples revealed two patients with
mutations predicted to affect WT1 activity; of these two samples, only one corresponded
to the low PRKCα expression cohort. Further characterization of the role of WT1 in
AML, and further understanding of WT1 regulated PRKCα expression, will be gained
following RPPA analysis of protein expression in HL60 leukemia cell lines with
lentiviral delivered shRNA knockdown of WT1 and shRNA knockdown of PRKCα.
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Chapter 1 – Introduction
Wilms tumor and Wilms Tumor Gene 1:
Wilms tumor is the most common childhood kidney tumor, occurring in 1 of
every 10,000 live births. Tumors arise from the undifferentiated metanephric
mesenchyme and can occur both unilaterally and bilaterally; sporadic and familial forms
of the disease exist, with the majority of tumors being unilateral and sporadic. Cases of
Wilms tumor can be accompanied by congenital anomalies such as sporadic aniridia,
hemihypertrophy, and genitourinary anomalies. The co-occurrence of Wilms tumor and
aniridia in disease patients allowed cytogenetic localization of WT1 tumor suppressor
gene at chromosome 11p13. WT1 encodes a protein with four c-terminal zinc fingers
shown to bind DNA and is inactivated in 15-20% of Wilms tumor cases (Background
Figure 1) (Bickmore et al., 1992; Huff, 1998).
WT1 is important during kidney development for correct formation of cellular
structures; interactions between the Wolffian duct and metanephric mesenchyme drive
the process of kidney formation as outgrowth of the Wolffian duct derived uteric bud
invades nearby nephrogenic mesenchyme and key molecules such as WT1 drive
downstream signaling cascade (Kuure, Vuolteenaho, & Vainio, 2000). As the uteric bud
comes into contact with uncondensed nephrogenic mesenchyme, the mesenchymal cells
begin to condense around the uteric bud in cap formations and undergo mesenchymal-toepithelial transition. In the mouse, this process of reciprocal signaling begins around
embryonic day 10.5-11 (E10.5-11) post conception. (Saxen, 1987). Asynchronous
mesenchymal-to-epithelial transition results in formation of early epithelial structures
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Background Figure 1: (left) histology of normal kidney with mesenchyme (M), s shaped
(S) and comma-shaped (C) bodies, and glomeruli. (right) Triphasic histology of Wilms
tumor exhibiting blastemal (B), stromal (F), and epithelial (E) components; lacks correct
formation of glomeruli and kidney nephron.
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known as comma-shaped and s-shaped bodies which ultimately become the mature
nephron. Staining of early embryonic mouse kidney reveals Wt1 expression localized to
the uncondensed mesenchyme and urogenital ridge that includes the early mesonephros
(Armstrong, 1992). During early phases of kidney development, Wt1 expression levels
are high with maximal expression in the comma-shaped and s-shaped bodies; Wt1
expression decreases with continued epithelialization, and is eventually restricted to the
podocytes of the mature nephron (Background Figure 2) (Pelletier et al., 1991;
Pritchard-Jones, 1990).
Conventional knockout of Wt1 is embryonic lethal with failure to develop
kidneys and gonads as well as phenotypes of the heart, liver, retina and spleen
(Kreidberg, 1993). Conditional Wt1 mouse models have confirmed the role of Wt1 in the
mesenchymal to epithelial transition in the kidney specifically (Miller-Hodges &
Hohenstein, 2012); knockdown of Wt1 results in incorrect formation of kidney nephron
(Davies et al., 2004) and mice die pre or perinatally (Herzer, 1999; Kreidberg, 1993).
Wt1 conditional knockout mice induced for mutant WT1 expression at E11.5 in the
context of Igf2 biallelic expression have been shown to develop tumors closely
resembling the histology of the human tumors and serve as the first model for Wilms
Tumor disease (Hu et al., 2011).
Wilms tumors are characterized by a distinct triphasic histology consisting of
blastemal, epithelial, and stromal components. Tumor histology closely resembles
embryonic kidney and lack correct formation of glomeruli and kidney; leading to the
hypothesis that tumors arise early during embryonic development, during the
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Background Figure 2: The structure of WT1 ZNF transcription factor consists of a four
zinc finger DNA binding domain with a three amino acid insert in exon 9, and a
transactivation domain with an alternative splice site at exon 5.
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mesenchymal to epithelial transition (Background Figure 3). Early mesenchymal
progenitor cells are thought to give rise to tumors following genetic changes that drive
aberrant cellular differentiation. In order to identify changes in cellular expression
contributing to tumorigenesis, gene expression arrays and protein expression arrays have
been carried out and identified a number of altered signaling pathways; tumors
expressing genes Six1, PAx2, and Eya1 suggest a nephrogenic mesenchyme progenitor
origin for tumors (Hu et al., 2011). Recently, protein expression arrays of human Wilms
tumors have identified several protein expression changes hypothesized to contribute to
tumorigenesis (Figure 1). Reverse phase protein array (RPPA) data indicates that when
grouped by mutation status, tumor samples harboring WT1 mutations have a significant
decrease in PRKCα (p-value, 0.00013) and p-PRKCα S657 (p-value, 0.00373) protein
expression. These data suggest that the WT1 transcription factor regulates PRKCα, and
that PRKCα plays a potential role in Wilms tumor tumorigenesis. We hypothesize that
the WT1 transcription factor directly/indirectly regulates PRKCα and mutations
occurring in WT1 lead to decreased expression of PRKCα.

5

WT1 TRANSCRIPTION FACTOR

Background Figure 3: WT1 ZNF transcription factor is detectable in the metanephric
mesenchyme of the developing kidney. Increased expression is seen in the condensing
mesenchyme as the developing kidney progresses through formation of the early
epithelial structures: the s-shaped and comma-shaped bodies. Expression is eventually
restricted to the podocytes of the mature nephron.
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Figure 1: RPPA heatmap (supervised hierarchical clustering) of Wilms tumor protein expression shows that patients with a WT1 mutation have
significantly decreased levels of PRKCα (p=0.00012) and p-PRKCα S657 (p=0.00372) expression.
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Protein Kinase C alpha:
PRKCα belongs to a serine/threonine family of kinases ubiquitously expressed in
vertebrates and responsible for multiple cellular processes (Nishizuka, 1988). PRKCα is
a conventional (classical) type PKC and is implicated in a variety of biological responses
such as apoptosis, proliferation, differentiation, and tumorigenesis, depending on tissue
localization (Nakashima, 2002). PRKCα is primarily expressed in the heart, brain, liver
and blood, although it can be detected in almost all organs. The PRKCα knockout mouse
is viable with no external phenotypes – a surprising result based on its ubiquitous
expression – but does show increased insulin signaling through the PI3K pathway
(Letiges et al., 2002). Knockout mice have been used to identify a role for PRKCα in
cardiovascular disease, pulmonary disease, platelet function, and immune cell function,
as well as multiple types of cancer (Konopatskaya & Poole, 2010). In tumorigenesis
specifically, PRKCα has been implicated in driving a more aggressive and metastatic
phenotype for human breast cancer cells (Sun & Rotenberg, 1999; Ways et al., 1995)
and overexpression of PRKCα has also been shown to contribute to the development of
renal cell carcinoma (Chuize et al., 2010).
PRKCα conformation regulation is a well-described and tightly controlled
process requiring diacylglycerol (DAG) and Ca2+ signals for activity (Background
Figure 4) (Dekker & Parker, 1994; Jaken, 1996). An original phosphorylation event by
PDK-1 in the activation loop of PRKCα at T497 leads to two secondary
autophosphorylation events at T638 in the protein turn motif and S657 in the
hydrophobic motif. Following the phosphorylation of PRKCα, conformational changes
in the molecule result in a pseudosubstrate sequence occupying the active site of the
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Background Figure 4: PRKCα protein structure consists of N-terminal regulatory, Cterminal catalytic, and V3 hinge regions. Active PRKCα is tightly regulated by three
mechanisms: phosphorylation, cofactor binding, and intracellular localization. The Nterminus regulatory region requires DAG and Ca++ binding, and contains several
phosphatidyl serine binding domains. The C-terminus catalytic domain is highly
conserved across the three PKC subfamilies and binds ATP and substrate targets.
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catalytic region; the PRKCα molecule is now considered ‘primed,’ but inactive (Griner
& Kazanietz, 2007). Because of this N-terminal autoinhibitory mechanism, PRKCα is
unable to bind and phosphorylate other substrates until DAG and Ca2+ signals are
received (Parekh, Ziegler, & Parker, 2000). Once DAG and Ca2+ cofactor binding takes
place, PRKCα is catalytically active and able to bind targets. Experiments have shown
that of the three phosphorylation events that occur, phosphorylation at T497 is required
to achieve full PRKCα activity, and therefore is most commonly used to assess for
PRKCα catalytic status (Parekh et al., 2000).
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Wilms Tumor Gene 1 and Acute Myeloid Leukemia:
A second part of this study is an investigation into the role of WT1 in acute
myeloid leukemia (AML) disease progression. Studies have suggested that WT1
mutation status may serve as a novel, independent poor prognosis factor for leukemia
disease progression and an appropriate target for therapy development (Virappane et al.,
2008). Patients harboring a WT1 mutation are more likely to have worse disease-free
survival (DFS), worse overall survival (OS), and increased drug resistance (KingUnderwood & Pritchard-Jones, 1998; Paschka et al., 2008). In AML patient mutation
analysis studies, WT1 mutations occur at a frequency of approximately 10%, cluster to
exons seven and nine, and are associated with failure to achieve a complete remission
(King-Underwood, Renshaw, & Pritchard-Jones, 1996). While the mechanisms by which
WT1 mutant protein may contribute to leukemia disease progression are poorly
understood, independent observations that leukemia patients can be categorized into high
and low expressing PRKCa groups has suggested that the same relationship between
WT1 and PRKCα, hypothesized to contribute to Wilms tumor, may also play an
important role in leukemia. In both diseases, we hypothesize that Wt1 transcription
factor is driving PRKCα expression levels. If this is true, we expect that leukemia
patients with WT1 mutations also have decreased PRKCα expression.
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We hypothesize that the WT1 transcription factor directly/indirectly
regulates PRKCα and mutations occurring in WT1 lead to decreased expression of
PRKCα. Understanding the relationship between WT1 and PRKCα will lead to
increased knowledge of the mechanisms leading to Wilms tumorigenesis and better
define the role of WT1 mutation status as a possible prognosis factor in AML.
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Chapter 2: WT1 co-localizes with PRKCα and Mutant WT1 affects PRKCα
gene expression during kidney development
Introduction:
If PRKCα is a transcriptional target of WT1 in the developing kidney, and an
important protein for correct kidney development, it should be expressed in the same cell
types as WT1. As previously discussed, WT1 expression is maximal in the embryonic
kidney during the mesenchymal to epithelial transition as kidney progenitors give rise to
early epithelial structures, comma-shaped and s-shaped bodies, before formation of the
mature nephron. Wilms tumor histology shows an incomplete formation of the kidney
nephron and a lack of epithelial structures, suggesting that tumors arise early as a result
of disruption in correct signaling necessary for kidney development.
We hypothesize that WT1 is regulating PRKCa expression at this important
developmental stage and mutation of WT1 results in changes in PRKCα expression that
contribute to a lack of complete mesenchymal to epithelial transition. Using a
combination of in-vivo and in-vitro models we should be able to establish that the two
proteins are co-expressed within the same cell types during kidney development.
Furthermore, utilizing Wt1 knockout mice and other models for manipulating WT1
expression levels, we should be able to demonstrate that increasing or decreasing WT1
expression results in reciprocal changes in PRKCα expression.

13

Materials/Methods:
Wt1 conditional knockout mice:
A mutant mouse strain carrying a Wt1 allele in which exons 8 and 9 are flanked
by loxP sites was generated by homologous recombination in previous studies (Gao et
al., 2006) and combined with an Estrogen-Cre (Cre-ER) transgene. Tamoxifen treatment
was shown to drive expression of Cre recombinase, resulting in an in-frame deletion of
exons 8 and 9, and a functional knockout of Wt1 activity. Exons 8 and 9 encode zinc
fingers 2 and 3 of wild type WT1 protein and their deletion results in an allele (Wt1Δ)
that acts as a null allele, as predicted by in-vitro studies (Hossain & Saunders, 2001;
Nachtigal et al., 1998; Royer-Pokora et al., 2004). For this study, crosses were set up
with females’ genotype Wt1fl/fl and males’ genotype Wt1+/-; Cre-ERTM. Pregnant females
were injected with 3 mg (3mg/40g) Tamoxifen at E11.5 to ablate Wt1 in the developing
embryo and achieve Wt1-/Δ mutant embryos with Wt1+/Δ control embryos. Mice were
genotyped by PCR to confirm Wt1 ablation. Primer sets and PCR conditions used are
listed in Table 1.

Isolation of mouse tissues:
Mutant (Wt1-/Δ;Cre-ERTM) and littermate control mouse embryos were harvested
at E13.5, E14.5, and E15.5 and kidneys isolated. For protein expression analyses kidneys
were sonicated and stored in protein lysis buffer (20mM Tris pH 7.5, 150mM Nacl,
1mM EDTA, 1% Triton X-100 (Sigma-Aldrich), 1X Protease Inhibitor Cocktail (SigmaAldrich). Embryonic kidneys for qPCR analysis were stored in TRIzol (Invitrogen) and
then homogenized. RNA was isopropanol precipitated, washed with 70% ethanol and
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5’CCATTTGTCACGTCCTGC3’
5’GAAACTGTTTGTAACGAGAG3’

5’GTGACCCCGCAGCTAGCC3’
5’TGCCTACCCAATGCTCATTG3’
5’TCCAATTTACTGACCGTACACCAA3’
5’GCTAACATATGGGAGACATT3’

Wt1 null allele

Wt1 flox allele

Cre-ERTM transgene

Wt1Δ allele

Cycle Conditions: 94 °C - 3 min, [94 °C - 45 sec, 58 °C - 45 sec, 72 °C - 50 sec] - 35 cycles, 72 °C - 7 min

5’TGCCTACCCAATGCTCATTG3’

5’CCTGATCCTGGCAATTTCGGCTA3’

Reverse Primer

Forward Primer

Detected

Table 1

45bps

600bps

150 and 200bps

250bps

Product Size

DNase 1 (Applied Biosystems) treatment to remove any DNA contamination.
Embryonic kidneys for immunohistology/immunofluorescence analysis were collected
and stored in 4% paraformaldehyde (PFA) overnight before paraffin embedding and
sectioning for mounting on slides.

Tissue culture:
Kidney mesenchymal cells line F7346, Clone 10, E6, Wt1+/fl; Immorto was
generated from cells isolated from mouse embryo and characterized as metanephric
mesenchyme cells expressing Wt1 (Nosavanh MS Thesis 2011). Cells have been shown
to be positive for mesenchymal cell marker, vimentin and negative for epithelial cell
marker, cytokeratin. Cell cultures were maintained in 10% FBS (fetal bovine
serum)(Hyclone) in 1X DMEM supplemented with interferon gamma purchased from
Sigma-Aldrich and 100 ug/mL of antibiotics (penicillin, streptomycin, and amphotericin
B) purchased from MediaTech at 33 °C. Cultures were genotyped using gene specific
primers and characterized as maintaining a mesenchymal morphology of elongated,
spindle-shaped, fibroblastic appearance (Table 1).
Human Embryonic Kidney cell line 293, HEK293, and M15, a mouse
mesenchymal cell line, were cultured in 10% FBS (Hyclone) in 1X DMEM
supplemented with 100 u/ML penicillin/streptomycin at 37 °C. T-RexTM -293(-KTS) and
T-RexTM -293(+KTS) were further supplemented with Zeocin and Blasticidin and
induced with 1ug/mL tetracycline for the indicated time. Cells lysates were collected for
downstream applications using scraping spatulas in protein lysis buffer (described in
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methods for isolating mouse tissues) for western blot analysis. RNA was isolated using
Qiagen RNeasy kit according to the protocol.

Immunohistochemistry:
Wild-type E14.5 kidney sections were stained for protein expression using
Vectastain ABC (avidin-biotin-peroxidase) kit (Vector Laboratories) according to the
protocol. Antibody to WT1 (mouse monoclonal antibody clone 6F-H2) was purchased
from Dako. Antibodies to PRKCα (rabbit monoclonal antibody Y124) and p-PRKCα
T497 (rabbit monoclonal antibody) were purchased from Abcam. Deparaffinized slides
were treated with 95-100 °C citrate buffer for antigen retrieval and allowed to cool to
room temperature before blocking with 3% hydrogen peroxide in PBS for 10 min. Slides
were washed three times in PBS and incubated for 1 hr in 10% BSA (bovine serum
albumin) in PBS at room temperature followed by incubation with primary antibody in
10% BSA in PBS overnight. Following primary antibody incubation, the slides were
washed three times in PBS and species-specific secondary antibodies were added in PBS
for 1 hr at room temperature (1:400). Vectastain ABC reagents were used according to
the protocol for color development and slides were counterstained with hematoxylin and
clear mounted using Permount (Fisher) after xylene dehydrating.

Immunofluorescence:
For immunofluorescence studies of cultured cells, cells were trypsinized, added
to 24-well plates containing glass discs, and allowed to adhere overnight before
methanol fixation at -20 °C for 15 min. For immunofluorescence studies of tissues
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sections, slides were deparaffinized and treated with citrate buffer as described in
immunohistochemical analysis above. After cooling to room temperature, slides were
incubated with 1% glycine in 0.1% TWEEN-20 (Sigma-Aldrich) in PBS for 1 hr. Both
discs of cultured cells and tissue slides were then washed twice in PBS followed by a 1
hr incubation with 15% NGS (normal goat serum) and slides/discs were incubated with
primary antibodies diluted in 2% NGS and left at 4 °C overnight. Slides/discs were then
washed three times in PBS and incubated with secondary antibodies Alexa Fluor-594
and/or Alexa Fluor-488 (Invitrogen, according to species-specificity) for 1 hr in the dark.
Subsequently, the slides/discs were washed three times in PBS and stained using
ProLong Gold antifade reagent with DAPI (Invitrogen) and allowed to air-dry overnight
at room temperature in the dark.

Western Blot Analysis:
Protein blot analyses were carried out as previously described (Gao et al., 2006;
Hu et al., 2011) with modification. Briefly, protein lysates were denatured for 3 min at
97 °C with 10 uL β-mercaptoethanol reducing agent before loading into BIORAD MiniPROTEAN Tetra cell assembly using Mini-PROTEAN TGX Precast Gels with Laemmli
running buffer at 90 volts for 2 hrs. Following gel electrophoresis, proteins were
transferred to PVDF membranes using BIORAD Mini Trans-Blot cell assembly run at
70V for 2 hrs at 4 °C. Membranes with bound proteins were blocked for 1 hr in 5% milk
in TBST (1X Tris buffered saline/0.1% Tween-20) followed by incubation with primary
antibody in 5% milk in TBST overnight at 4 °C (primary antibodies described in
methods for immunohistochemical analysis). Primary antibody incubation was followed
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by 3 washes in TBST and a 1 hr incubation with species-specific secondary antibody
diluted 1:5000 in 5% milk in TBST at room temperature. Following a 3 washes in
TBST, membranes were developed using SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific) according to the protocol.

RT-PCR/qPCR Analysis:
RNA for gene expression by SYBR Green assays (Applied Biosystems). First,
RNA was quantified, normalized across samples and mixed with MultiScribe Reverse
Transcriptase and PCR Master Mix according to the protocol for cDNA synthesis
(Invitrogen). cDNA samples were mixed with SYBR Green reagent and forward and
reverse primers for detecting expression levels of specific genes and amplified using
ABI 7900 HT sequence detection system (Applied Biosystems). Gene specific Ct values
were compared across samples relative to Gapdh endogenous control levels and
calculated as fold differences to a control reference value whose expression was
designated as 1. qPCR primer sequences are listed in Table 2.

siRNA Transfection:
Knockdown of Wt1 in mouse mesenchymal cell line M15 was achieved by
transient transfection of scrambled Wt1 siRNA (ON-TARGET plus SMARTpool duplex,
Dharmacon) using media supplemented with 10uL of HyperFect Transfection Reagent
(Qiagen). Cells were plated into 6 well plates at 8x104 cells per well and allowed to grow
overnight before adding 50nm siRNA. Following 24hrs of Wt1 siRNA treatment, RNA
and protein lysates were collected as described in methods for tissue culture.
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Reverse Primer
5’TTCAAGCTGGGAGGTCATTT3’
5’CAGGATCTTGATGGCGTACAGTT3’
5’CGTTCACACCGACCTTCAC3’
5’AAGCTGGGATGTCATTTGGT3’
5’CCTTCCGGAATGGGTACGT3’
5’ACCTTCCCCATGGTGTCTGA3’

Forward Primer
5’AGTTCCCCAACCATTCCTTC3’
5’TTGGGAAGGTGATGCTTGCT3’
5’CTCTCTGCTCCTCCCTGTTC3’
5’CAGTTCCCCAACCACTCATT3’
5’CCAGTGGATGGTACAAGTTGCTTA3’
5’GCTCCTCCTGTTCGACAGTCA3’

Wt1 (mouse)

Prkcα (mouse)

Gapdh (mouse)

WT1 (human)

PRKCα (human)

GAPDH (human)

Table 2

Results:
Immunohistochemical staining of wild type E14.5 mouse kidney for WT1 and
PRKCα confirms that both proteins are expressed in the uncondensed mesenchyme
during kidney development. Robust WT1 expression is seen in the uncondensed
mesenchyme of the fetal kidney as well as in the comma and s-shaped body early
epithelial structures and is eventually restricted to the podocytes of the mature nephron
(Figure 2, top). Cells and epithelial structures positive for WT1 expression show strong
nuclear staining. Likewise, PRKCα staining shows a positive signal in the uncondensed
mesenchyme of E14.5 mouse kidney. Positive cells show largely cytoplasmic staining
for PRKCα protein. Additionally, PRKCα is expressed in proximal and distal tubules
and mesangeal cells of the fully formed glomerulus; again, the signal is largely
cytoplasmic (Figure 2, middle). Staining for the phosphorylated isoform of PRKCα, pPRKCα T497 (Abcam, rabbit monoclonal antibody), shows a positive signal in the
uncondensed mesenchyme, proximal and distal tubules, and mesangeal cells, an
expression pattern identical to pan PRKCα (Figure 2, lower).
Double immunofluorescent staining of E14.5 wild type mouse kidney for WT1
and PRKCα confirms co-localization of the proteins in the developing glomerulus. Early
epithelial structures show strong nuclear staining for WT1 and cytoplasmic staining for
PRKCα. Both proteins are expressed in the same cells of the comma-shaped body, but
largely within different cell compartments (Figure 3).
Similarly, double immunofluorescent staining of mesenchymal cell cultures
confirms co-localization of WT1 and PRKCα. Kidney mesenchymal cell line F7346
shows strong nuclear expression of WT1 and strong nuclear/cytoplasmic expression of
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Figure 2: (top panel) WT1 IHC of wild type E14.5 mouse kidney shows staining of condensing mesenchyme, early epithelial structures, and
podocytes. (middle panel) PRKCα IHC of wild type E14.5 mouse kidney shows light staining of condensing mesenchyme, proximal and
distal tubules, and mesangial cells of the glomerulus. (lower panel) p-PRKCα T497 IHC of wild type E14.5 mouse kidney shows identical
staining as total PRKCα IHC; the condensing mesenchyme, proximal and distal tubules, and mesangial cells are all positive.
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Figure 3a: Double IF staining shows co-localization of WT1 (red) and PRKCα (green) in the condensing mesenchyme of embryonic kidney;
PRKCα expression can also be seen in other structures of the developing kidney.
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Figure 3b: Double IF staining shows co-localization of WT1 (red) and PRKCα (green) in the condensing mesenchyme of embryonic kidney;
specifically, within a comma-shaped body early epithelial structure.
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Figure 3c: Deconvolution microscopy double IF staining shows co-localization of WT1 (red) and PRKCα (green) in the condensing
mesenchyme of embryonic kidney; specifically, within a comma-shaped body early epithelial structure.

DAPI & WT1/PRKCα

PRKCα. p-PRKCα T497 also shows robust expression (Figure 4). These data confirm
that PRKCα co-localizes with WT1 during embryogenesis and kidney development.
In previous experiments I have shown M15 cells to co-express nuclear WT1 and
cytoplasmic PRKCα. Following 24hrs of Wt1 siRNA treatment, a 21% decrease in Wt1
RNA levels and a resulting 78% decrease in Prkcα RNA levels was measured by qPCR.
At the protein level, by western blot analysis, a decrease in WT1 protein was also
detected, as well as a decrease in PRKCα protein expression (Figure 5). In the reverse
experiment T-RexTM -293(-KTS) cells, in which WT1 was over-expressed using 1ug/mL
tetracycline induced WT1(-KTS) expression for 24hrs, an 11-fold increase in WT1 RNA
expression was assessed by qPCR. Following the significant increase in WT1 RNA
expression, a 40% increase in PRKCα RNA expression was observed. Western blot
analysis of protein expression confirms this relationship at the protein level; using cell
lines T-RexTM -293(-KTS) and T-RexTM -293(+KTS), both –KTS and +KTS isoforms of
WT1 are increased after being induced with tetracycline and result in an increase in
PRKCα protein level. Interestingly, results shows that at the protein level the +KTS
isoform of WT1 results in a much greater increase in PRKCα expression, as compared to
the –KTS isoform (Figure 6).
In-vivo deletion of Wt1 on Prkcα gene expression was measured using WT1
functional knockout mice. A breeding strategy producing Wt1-/fl; Cre-ERTM mutant mice
was used to ubiquitously ablate WT1 function at E11.5 days of development in mice
embryos. In-utero tamoxifen injection (3mg/40g) at the E11.5 timepoint, disrupts kidney
development and results in a 64% decrease in wild type Wt1 RNA by E13.5. This
decrease in Wt1 RNA results in a 70% decrease in Prkcα RNA. Likewise, ablation of
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Figure 4a: Double IF staining shows co-localization of WT1 (red) and PRKCα (green) in kidney mesenchymal cell line M15.
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Figure 4b: Deconvolution microscopy double IF staining shows co-localization of WT1 (red) and PRKCα (green) in the kidney mesenchymal
cell line M15.
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Figure 5: (a) qPCR analysis, siRNA knockdown of Wt1 in M15 cell culture resulted in
20% decrease in Wt1 RNA expression (p=0.021) and (b) an 80% decrease in Prkcα
RNA expression (p=0.042) in comparison to luciferase siRNA control experiments. (c)
Knockdown of Wt1 expression is confirmed at the protein level, and a resulting decrease
in Prkcα protein expression is seen.
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Figure 6: (a) qPCR analysis, tetracycline inducible WT1 expression in HEK293 cells
increases WT1 RNA expression by more than 10-fold (p=0.000019) and (b) a resulting
40% increase in PRKCα RNA expression (p=0.032) is observed. (c) Protein expression
data show an increase in WT1 after cell lines are induced with tetracycline. Both -kts
and +kts isoforms of WT1 protein are induced and result in downstream increase in
PRKCα protein expression, particularly the +kts isoform.
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WT1 measured at E15.5 shows a 78% decrease in wild type Wt1 RNA and a 40%
decrease in Prkcα RNA. Western blot analysis also confirms this trend, with a
significant decrease in PRKCα protein expression in E14.5 Wt1 knockout embryos
observed (Figure 7). Furthermore, the effects of mutant WT1 on PRKCα were evaluated
using human Wilms tumor patient RNA. qPCR analysis of PRKCα RNA expression
confirms changes in expression originally seen at the protein level in RPPA experiments.
It was found that patients with a mutation in WT1 have a 74% decrease in PRKCα RNA
expression (Figure 8).
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Figure 7: (a) Breeding strategy used to achieve Wt1 mutant mouse, (b) and Cre-ER, a
tamoxifen-inducible Cre-expressing transgene used to ablate Wt1 function. (c) Mice
were injected at E11.5 with 3mg TM, and tissues were collected at E13.5 and E15.5. (d)
qPCR analysis, at E13.5 a 60% ablation in Wt1 RNA expression (p=0.0017) is observed,
with a resulting 70% decrease in Prkcα RNA expression (p=0.0001). (e) At E15.5 an
80% decrease in Wt1 RNA expression (p=0.0064) is observed, with a resulting 40%
decrease in Prkca RNA expression (p=5.87E-6). (f) Western analysis shows a decrease
in Prkcα expression at the protein level following Wt1 ablation.

34

Patient Sample RNA Expression
1.2
1
0.8

*

0.6

Wild Type (n=9)
Mutant WT1 (n=5)

0.4

***
0.49

0.2

0.26
0
WT1

PRKCA

Figure 8: qPCR analysis of Wilms tumor patient samples shows a 50% decrease in WT1
expression (p=0.028) at the RNA level and a 70% decrease in PRKCα RNA expression
(p=0.0010). These data support results of the original RPPA heatmap data that showed
comparable changes at the protein level.
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Discussion:
My ability to demonstrate that WT1 and PRKCα are both expressed in the
uncondensed mesenchyme of the developing kidney strengthens the possibility that WT1
transcription factor regulates Prkcα expression. WT1 staining is largely nuclear in the
uncondensed mesenchyme of E14.5 mouse kidney while PRKCα expression is
cytoplasmic, confirming that regulation of Prkcα at the transcription level by WT1 takes
place within the nucleus before PRKCα is shuttled to cytoplasmic regions where it is
catalytically active (Nakashima, 2002). Phosphorylation of PRKCα at the T497 residue
is considered essential for kinase activity (Cazaubon, 1994) and therefore p-PRKCα
T497 is expected to localize to regions beyond the cell nucleus. By immunostaining for
the T497 residue and localizing its expression to the cytoplasm, I have demonstrated that
the phosphorylated form is present in the kidney, consistent with the hypothesis that
WT1 is regulating a catalytically active form of PRKCα. WT1-PRKCα
immunofluorescent staining of embryonic kidney structures provides further evidence
for protein co-localization. Positive staining for WT1 and PRKCα can be clearly seen in
the epithelializing cells of a comma-shaped body in E14.5 mouse kidney. As discussed
earlier, WT1 expression becomes restricted to the epithelial structures of the developing
kidney as organogenesis proceeds (Pelletier et al., 1991; Pritchard-Jones, 1990). At the
E14.5 stage in mouse kidney, WT1 expression is mainly found in early epithelial
structures of the developing kidney. While immunohistochemical staining clearly
showed PRKCα and WT1 co-expression in the uncondensed mesenchyme, double
immunofluorescence staining of comma-shaped bodies further confirms that the two
proteins are expressed within the same cells at later stages in kidney development. This
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staining pattern suggests that transcriptional control of Prkcα by WT1 continues
throughout the mesenchymal-to-epithelial transition of kidney organogenesis. A final
method for confirming co-localization of WT1 and PRKCα in kidney mesenchymal cells
was achieved by in vitro staining of a kidney cell line F7346, derived from harvested
kidney mesenchymal cells. Mesenchymal kidney culture shows a clear co-expression of
WT1 and PRKCα and confirms both immunohistochemical and immunofluorescent data.
I was able to demonstrate by a number of methods that WT1 and PRKCα colocalize at a timepoint in kidney development at which cells can give rise to Wilms
tumor. Mutations in WT1 occurring before complete mesenchymal-to-epithelial
transition disrupt cellular differentiation and drive tumorigenesis. By showing that
PRKCα is expressed alongside WT1 in the uncondensed mesenchyme, before formation
of early epithelial structures and at a time during mesenchymal differentiation at which
Wilms tumors are though to arise, we have shown that it is possible that WT1 is
regulating Prkcα. While further evidence is needed to implicate Prkcα as a contributor to
Wilms tumorigenesis, these data, along with RPPA expression patterns in Wilms tumor
patients harboring WT1 mutations, strengthens the possibility of WT1 regulating PRKCα
expression. Prkcα is therefore a potential novel target of WT1 during kidney
development, and decreased expression of Prkcα may contribute to aberrant kidney
development and/or Wilms tumor.
Both knockdown and up-regulation experiments show that PRKCα is regulated
by WT1 in-vitro. M15 cells were previously shown to express both WT1 and PRKCα,
although in different subcellular components (Figure 4). In-vitro knockdown
experiments using Wt1 targeted siRNA show that a decrease in Wt1 RNA expression
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results in a significant decrease in Prkcα RNA expression. This result suggests that WT1
is in fact regulating Prkcα gene expression. Furthermore, changes in gene expression at
the RNA level are mirrored at the protein level with a decrease in PRKCα protein
expression a result of decreased WT1 protein expression. M15 cell culture is a mouse
mesenchymal cell culture; this data, demonstrates that the regulatory relationship
between WT1 and PRKCα, originally seen in human tumors, is maintained in cells that
are important to kidney formation and implicated in tumorigenesis.
In the reverse experiment, WT1 increased expression is driven by tetracyclineinducible system in human embryonic kidney cells line, HEK293. As predicted by our
hypothesis, a significant increase in WT1 RNA and protein levels results in a significant
increase in PRKCα RNA and protein levels. Together, knockdown and up-regulation
experiments in kidney cells specific to embryogenesis support our hypothesis that WT1
is regulating PRKCα expression. In-vitro experiments provide a system not confounded
by complex histology or genotype and retain the positive regulatory relationship between
the genes in question, providing compelling evidence in support of our hypothesis.
By using a mouse model for Wt1 functional knockout, we were able assess WT1
regulation of Prkcα and validate in-vitro findings in-vivo. In order to achieve the highest
level of biological relevance with regard to Wilms tumorigenesis, gene expression levels
were assessed at E13.5-E15.5 days, a period important for correct cellular formation of
the embryonic kidney. RNA levels assessed at E13.5 and E15.5 showed the expected
knockout of wild-type WT1 and a resulting decrease in Prkcα RNA levels. It is
important to note that a greater level of decreased Prkcα RNA expression was observed
at E13.5 as opposed to E15.5 timepoint. This data can be explained histologically; as the
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kidney undergoes signaling between uncondensed metanephric mesenchyme and the
invading uteric bud, cell populations differentiate and give rise to diverse structures not
implicated in Wilms tumorigenesis. Previously, we identified cells populations not
implicated in tumorigenesis as expressing Prkcα. As the embryonic kidney
differentiates, these populations increase and therefore there is greater PRKCα in the
total kidney. In order to confirm in-vivo changes at the protein level, embryonic kidney
expression was assessed at the E14.5 timepoint. As expected, there was a decrease in
PRKCα protein levels following knockout of wild-type WT1 protein.
For further analysis of WT1 and PRKCα expression levels we assessed human
Wilms tumor patient samples, originally used for RPPA analysis, for RNA expression
levels. We were able to confirm changes in gene expression in patients harboring WT1
mutations, originally seen at the protein level, at the RNA level. Patients with mutations
in WT1 were found to have significantly decreased PRKCα RNA levels.
While human RPPA data has already demonstrated that a decrease in wild type
WT1 correlates with decreased PRKCα protein expression in Wilms tumor, we have
been able to show in a variety of experimental systems that decreased WT1 expression
leads to decreased PRKCα expression. In both human and mouse systems we were able
demonstrate that PRKCα expression is positively correlated with WT1 expression.
Similarly, by utilizing in-vitro models, we were able to eliminate variables that exist in
in-vivo models such as multiple cell types, to confirm that intra-cellular control of
PRKCα expression is maintained by WT1. It is still imperative to determine if regulation
of PRKCα by WT1 is a direct or indirect process. It is possible that WT1 transcription
factor binds the PRKCα promoter region directly to control transcriptional activation,
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but it is also possible that PRKCα falls further downstream of WT1 transcriptional
activity. Overall, there is compelling evidence that WT1 does in fact regulate PRKCα
expression directly or within close proximity as we observed strong correlation between
WT1 and PRKCα expression levels.
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Chapter 3: Identification of WT1 binding sites in PRKCα regulatory regions
Introduction:
The data presented in the previous chapter show that PRKCα expression at both
the RNA and protein level is dramatically reduced or increased following, respectively,
loss of WT1 function or up-regulation of WT1 expression. However, further evidence is
needed to support the hypothesis that WT1 directly transcriptionally regulates PRKCα.
The Wilms tumor gene encodes a DNA-binding protein containing four c-terminal
Cys2His2 zinc fingers shown biochemically to bind target DNA (Background Figure 2)
(Stoll et al., 2007). While originally thought to behave like a typical Early Growth
Response (EGR) family transcription factor, the function of WT1 has proven to be more
complex (Ladomery & Dellaire, 2002). The primary WT1 transcript is alternatively
spliced into four isoforms depending on the presence or absence of exon 5 and a three
amino acid insert (KTS) between zinc fingers 3 and 4 of the protein (Call et al., 1990;
Gessler et al., 1990). Previous studies have found no major developmental implications
concerning the exclusion of exon 5 from the final transcript, and therefore is not a focus
of this study (Natoli et al., 2002); however, there are significant implications to protein
activity based on +KTS vs. –KTS splice variants and their expression ratios (Hammes et
al., 2001; Klamt et al., 1998). +/- KTS isoforms have been show to localize to different
areas of the cell and preform unique roles. The –KTS isoform is localized to the cell
nucleus and has been shown to be transcriptionally active, while the +KTS isoform is
localized to the splicesome complex and largely plays a post-transcriptional role (Haber
et al., 1991; Larsson et al., 1995).

41

Previous work has shown that WT1 protein preferentially binds GC-rich regions
similar to EGR-1 consensus binding site 5’GCG-(T/G)GG-GCG3,’ although with loose
consensus and isoform specificity (Bickmore et al., 1992; Rauscher, Morris, Tournay,
Cook, & Curran, 1990). Alternatively, WT1 transcription factor has also been shown to
bind sequences 5’TCCTCCTCCTCCTCTCC3’ and 5’GCGTGGGAGT3,’ as well as
others, depending on cell type and expression levels (Nakagama, Heinrich, Pelletier, &
Housman, 1994; Wang, Qiu, Enger, & Deueul, 1993). Due to the loose consensus and
poorly characterized binding sites of WT1, it is necessary to experimentally demonstrate
WT1 binding of target sequences to prove transcriptional regulation. In this case it is
necessary to predict possible WT1 binding sites within the PRKCα promoter and
demonstrate transcriptional regulation by WT1 using reporter assays.
The human PRKCα gene shows a high level of conservation, >98% homology
between species, with shared homology to the murine transcription start site and
promoter specifically (Clark, Haridasse, & Glazer, 2002; Desai, Hirai, Karnes, Niles, &
Ohno, 1999; Finkenzeller, Marme, & Hug, 1990). Glazer et al. mapped and
characterized the human PRKCα promoter in great detail and identified a number of
important features. Basal promoter activity is restricted to a region from -227 to +77
relative to the transcription start site, which was narrowed further by deletion constructs
to the sequence from -227 to -106. Within this region an activator protein-2 (AP-2)
binding site was identified and shown to increase transcription when overexpressed, and
multiple other AP-2 and Sp1 binding sites were identified throughout the promoter
region. While post-transcriptional activation of PRKCα gene is a well-understood
process, few studies have been carried out to better understand transcriptional regulation
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of PRKCα due to its ubiquitous expression. In order to determine if WT1 transcription
factor binds and regulates PRKCα, the cloned human sequence was obtained from
Glazer et al.
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Materials/Methods:
Promoter Constructs and Luciferase Reporter Assay:
Three PRKCα promoter constructs, -1571/+77, -227/+77, and -106/+77, were
received from Robert Glazer, Ph.D. (Professor, Oncology and Pharmacology,
Georgetown University) (Figure 9) and sequenced to confirm 100% sequence identity to
human PRKCα. HEK293 cells were transfected with one of three pGL3-PRKCα
promoter vectors. In addition, luciferase activity control experiments using empty PGL3
vector were carried out to assess for background activity. In 24-well plates, 7.5x104
HEK293 cells were plated per well before experimentation. Into each well was added
300ng of PRKCα promoter construct as well as 5ng of Renilla (sea pansy luciferase)
construct for normalization. Following transfection using SuperFect Transfection
Reagent (Qiagen), the cells were incubated for 36hrs before trypsinization and assessing
for both firefly and Renilla activity using Dual-Luciferase Reporter Assay System
(Promega) according to the protocol.
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Figure 9: (a) WT1 binding sites identified in the PRKCα promoter region. Site A and B identified as BIOBASE predicted WT1 binding
sites, and Site C as a WT1/EGR-1 consensus site. (b) Diagram of promoter constructs used in luciferase reporter experiment; -227/+77
has the highest affinity for WT1 binding and -1571/+77 construct is also positive for WT1 binding. Both pGL3 Basic and -106/+77
negative control constructs show no WT1 binding activity.
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Results:
BIOBASE TRANSFAC© bioinformatics software was first used to assess
PRKCα regulatory regions for possible WT1 binding sites. Two predicted WT1 binding
sites were identified, located upstream of the PRKCα transcriptional start site and within
the predicted PRKCα promoter: 5’CCTCCTCCCCC3’ and 5’CCCTCCCCC3’. Both
sites are GC rich sequences, a feature commonly reported for WT1 target sequences. A
third site, closer to the transcription start site and not originally predicted by BIOBASE,
was identified by hand as a possible WT1 binding site. The third site, an EGR-1 site
binding site 5’CGCCCCCGC3,’ showed by consensus that it could possibly serve as a
WT1 binding sequence (Figure 9). Three PRKCα promoter constructs, -1571/+77, 227/+77, and -106/+77, were assessed for WT1 binding activity (Figure 9). The 1571/+77 PRKCα promoter construct contains all three predicted WT1 binding sites, the
-227/+77 PRKCα promoter construct contains only the EGR-1 consensus site, and the 106/+77 does not contain a predicted WT1 binding site. Luciferase reporter experiments,
in which HEK293 cells were transfected with one of three pGL3-PRKCα promoter
vectors, tested for up-regulation of PRKCα transcript by WT1. Cells transfected with the
-1571/+77 construct showed significantly increased luciferase activity in comparison to
the -106/+77 negative control construct, demonstrating that endogenous WT1 can drive
PRKCα expression and possibly binds the promoter directly. Moreover, cells transfected
with the -227/+77 construct showed significantly increased luciferase activity in
comparison to the -106/+77 negative control, as well as the -1571/+77 construct.
Interestingly, while the -1571/+77 construct contains all three predicted WT1 binding
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sites, it is the -227/+77 construct containing the EGR-1/putative WT1 binding site that
produced the strongest luciferase signal (Figure 9).
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Discussion:
Bioinformatic assessment predicts direct binding of WT1 to the PRKCα promoter
and Luciferase reporter experiments demonstrate that PRKCα expression is regulated by
WT1 transcription factor. While a number of possible WT1 binding sites were predicted,
the highest level of transcriptional activity was localized to a region from -227 to -106 of
the PRKCα promoter. Interestingly, this is the same region, previously described by
Glazer et al., that is required for basal activity (although this is attributed to AP-2
binding site). In order to confirm the predicted 5‘CGCCCCCGC3’ WT1 binding site as
the actual site of WT1 binding, it will be necessary to carry out mutation analysis of this
site. By altering the target sequence by even a few nucleotides we should be able to
obliterate WT1 binding ability (Shahidul Makki, Cristy Ruteshouser, & Huff, 2013).
Direct regulation of PRKCα by WT1, in conjunction with PRKCα expression
levels in Wilms tumors harboring WT1 mutations, implicates PRKCα as a possible
important player in tumorigenesis. Developmentally, WT1 mutations have been shown to
contribute to tumorigenesis through poorly defined signaling mechanisms - these results
suggest that WT1 signaling through PRKCα is a process important to normal kidney
organogenesis and that when normal signaling cascades downstream of WT1 and
PRKCα are disrupted, an environment favorable for tumor development is created.
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Chapter 4: Identification of WT1 and PRKCα downstream targets in-vitro
Introduction:
In Wilms tumorigenesis, mutations in WT1 lead to decreased PRKCα expression
in the developing kidney. We have shown that WT1 directly regulates PRKCα and that
gene expression is significantly decreased following WT1 knockdown. In order to better
understand the relationship between WT1 and PRKCα expression and the downstream
consequences of their dysregulation, it is important to determine targets of the two
proteins. According to our model, mutations leading to aberrant WT1 expression drive
gene changes through decreased PRKCα expression that contribute to Wilms
tumorigenesis; identifying and mapping downstream targets is important to
understanding the cellular micro-environments giving rise to Wilms tumor development.
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Materials/Methods:
Creation of Stable Cell lines:
M15, mesenchymal cells were transduced using lentirviral delivered shRNA.
Two separate MISSION TRC shRNA Custom Lentiviral Particles, pLKO-puro-IPTG3xLacO, targeting Wt1 and Prkcα were ordered (Sigma-Aldrich); as well as lentivirus
carrying non-target sequence negative control (NTC) shRNA. In 6 well plates, 1.5x104
M15 cells were seeded per well along with lentivirus at 0.5 MOI targeting Wt1, Prkcα,
or NTC. Cells were incubated in 1X DMEM with 10% FBS (Hyclone) media containing
lentivirus and 1000ng/mL puromycin selection antibiotic for 24hrs before fresh media
and antibiotic without lentivirus was added. Transduced cells were grown for an
additional six days under puromycin selection to ensure uptake of viral construct before
trypsinization and selection of single cells for subcloning into M15-Wt1-shRNA, M15Prkcα-shRNA, and M15-NTC-shRNA cell lines. Each cell line was then evaluated and
selected for low copy number by qPCR with primers to the Lac operon of the viral
construct. Low copy number was desired for creating a biologically relevant system in
which there is decreased probability of inserting sequence into genes important for
regular cell behavior. Also, too high of a copy number could possibly tax normal cellular
activities to a point of arbitrarily affecting experimental outcome. M15-Wt1-shRNA and
M15-Prkcα-shRNA cell lines were assessed by immunofluorescence for retention of
wild type M15 mesenchymal cell markers; cell lines remained positive for WT1 (Dako,
mouse monoclonal antibody clone 6F-H2), vimentin (Sigma-Aldrich, mouse monoclonal
antibody clone LN-6), and PRKCα (Abcam, rabbit monoclonal antibody Y124) proteins,
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and remained negative for cytokeratin (Sigma-Aldrich, pan mouse monoclonal antibody)
protein (Figure 10a/b).

shRNA Knockdown:
qPCR analysis confirmed knockdown of appropriate gene targets after 48hrs of
50uM IPTG induction.

PCR Array:
RNA lysates from both cell lines, following 48hrs of IPTG induction, were each
used in the Mouse Cancer PathwayFinder RT2 Profiler PCR Array (Qiagen) to profile
the expression of 84 genes representative of biological pathways involved in
transformation and tumorigenesis.

RPPA Analysis:
Changes in the protein expression of both cell lines were also assessed by
Reverse Phase Protein Assay (RPPA). Protein cell lysates were prepared according to
the protocol provided by MD Anderson Cancer Center, Dept. of Systems Biology,
Reverse Phase Protein Array Core Facility and submitted for analysis of differential
gene expression with 157 antibodies. Experiments were submitted in replicates of five in
order to obtain statistically significant results. Conversely, HEK 293 cells containing a
tetracycline inducible WT1 construct, T-RexTM -293 WT1(-kts), were assessed for
changes in protein expression following induced expression with 1ug/mL tetracycline
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Prkca Positive
Cytokeratin Negative

Vimentin Positive

Wt1 Positive
(a)

Normal M15
M15-Prkcα-shRNA
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Normal M15

M15-Prkcα-shRNA

M15-Wt1-shRNA

M15-NTC-shRNA

Figure 10: (a) Stable cell lines created using lentiviral delivered shRNA continue to express mesenchymal cell markers following
transduction. (b) Stable cell lines retain a cell morphology identical to original M15 cell population following transduction and
puromycin treatment.

(b)

for 24hrs. Protein cell lysates for induced and un-induced (control) experiments were
submitted in triplicate and evaluated with the same 157 antibodies.
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Results:
qPCR analysis of induced stable cell lines confirmed knockdown of appropriate
gene targets after 48hrs of 50uM IPTG treatment. M15-Prkcα-shRNA cell line showed a
76% knockdown of Prkcα, and M15-Wt1-shRNA cell line showed an 83% knockdown
of Wt1 (Figure 11a). M15-Wt1-shRNA cell lines were also assessed for RNA expression
of Prkcα since we hypothesize it to be a target of WT1. Previous work suggests that a
resulting decrease in Prkcα expression should be seen. However, no changes in Prkcα
RNA levels were identified. Western blot analysis of PRKCα protein levels following
Wt1 shRNA expression did show a decrease in PRKCα protein level (Figure 11b). No
change in cell morphology was seen in stable cell lines following 48hrs of IPTG
treatment (Figure 11c).
RNA lysates from both cell lines, following 48hrs of IPTG induction, were each
used in the Mouse Cancer PathwayFinder RT2 Profiler PCR Array (Qiagen) to profile
the expression of 84 genes representative of biological pathways involved in
transformation and tumorigenesis. 11 differentially expressed target genes were
identified following knockdown of Wt1 (Figure 12), and 17 differentially expressed
target genes were identified following knockdown of Prkcα (Figure 13). In both arrays,
the Vegf family of proteins was shown to have changed expression levels. No changes in
expression levels for genes encoding signal transduction molecules or transcription
factors were detected.
Changes in the protein expression levels of both stable cell lines were also
assessed by Reverse Phase Protein Array (RPPA) (Figure 14). Array results show a
number of changes following gene targeted knockdown. Significant gene expression
changes are listed in Tables 4.

55

(a)
M15-Prkcα-shRNA RNA Expression

M15-Wt1-shRNA RNA Expression

1.2

1.2

1

1
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0.8
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0.6

0.4

0.92
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0.91

0.4
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0
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Un-Induced
Un-Induced
Control
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Induced
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siRNA
shRNA

0.24
0
Wt1

Prkca

(b)

Wt1

Prkca

M15-Wt1-shRNA
Control

shRNA

p-PRKCα
T497
p-Prkca T497
PRKCα
Prkca
WT1
Wt1

Beta-actin
Beta-actin
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(c)
Induced, IPTG 48hrs

M15-Wt1-shRNA

M15-Prkcα-shRNA

Normal M15

Control

Figure 11: (a) 48hrs induction of shRNA by addition of IPTG into culture media
produces knockdown of target genes in both cell lines. In M15-Prkcα-shRNA cell line,
76% knockdown of Prkcα (p=0.011) is achieved. In M15-Wt1-shRNA cell line, 83%
knockdown of Wt1 (p=0.00019) is achieved. (b) Western blot analysis of protein levels
following induction of shRNA and knockdown of Wt1 target gene, confirms decreased
protein expression of both WT1 and PRKCα (total and unphosphorylated). (c) No
change in cell morphology is seen in stable cell lines following 48hrs of IPTG treatment.
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M15-Wt1-shRNA, WT1 downstream targets
3.00
2.50
2.00
1.64
1.50
1.00

1.58

1.63

1.50

1.57

1.61
1.37

1.55

1.47
1.17
0.80

0.50
0.00

Figure 12: PCR Array of M15-Wt1-shRNA (un-induced vs. induced plate) identified
11 differentially expressed target genes.
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M15-Prkcα-shRNA, PRKCα downstream targets
3.00
2.45

2.50

2.22
1.93

1.90

2.00
1.58 1.56 1.58 1.53 1.66 1.63

1.73

1.77 1.78

1.60 1.53

1.50
1.00
0.50
0.50
0.00
0.00

Figure 13: PCR Array of M15-Prkcα-shRNA (un-induced vs. induced plate) identified 17
differentially expressed target genes.
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0.405

Figure 14a: RPPA heatmap (supervised hierarchical clustering) of HEK 293 protein expression following induction of WT1 expression.

-1.14

(log)

Table 3

Significantly Increased
Bcl-2
Bcl-X
beta-Catenin
Chk2 pT68
cIAP
ER-alpha
HER2
HER3
HSP70
IGF-1R-beta
IGFBP2
NF2
Notch1
p21
S6 pS235 S236
S6 pS240 S244
Smac
STAT5-alpha
VASP
VEGFR2
YAP pS127
YB-1

p-value
0.04
0.04
0.03
0.03
0.03
0.03
0.02
0.00
0.04
0.05
0.01
0.03
0.00
0.00
0.01
0.01
0.03
0.03
0.00
0.04
0.02
0.03

Significantly Decreased
53BP1
Akt
Annexin I
Bim
Caveolin-1
Chk1 pS345
GATA3
Mre11
Notch3
p38 pT180 Y182
p53
Snail
STAT3 pY705
TTF1
XIAP
XRCC1

p-value
0.03
0.04
0.01
0.04
0.00
0.01
0.01
0.05
0.03
0.02
0.04
0.00
0.02
0.01
0.06
0.04
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Conversely, HEK 293 cells containing a tetracycline inducible WT1 construct, TRexTM -293 WT1(-kts), were assessed for changes in protein expression RPPA analysis
(Figure 14). RPPA heatmap data shows significant changes in protein expression in a
number of proteins, listed in Table 3.

62

63

0.957

3.37

-0.839

Figure 14b: RPPA heatmap (supervised hierarchical clustering) of M15-Prkcα-shRNA and M15-Wt1-shRNA following induced
expression of shRNA.

-0.957

(log)

-2.55

-1.611

(log)

Table 4

Putative Prkcα Targets
4E-BP1 pT37 T46
ACC pS79
Akt
C-Raf
Dvl3
GAB2
GATA3
GSK3-alpha-beta pS21 S9
GSK3 pS9
MAPK pT202 Y204
N-Cadherin
Notch1
p38 pT180 Y182
p70S6K
p70S6K pT389
PKC-alpha
PKC-alpha pS657
PTEN
S6 pS235 S236
S6 pS240 S244
STAT5 alpha

Increased (Inc.) vs. Decreased (Dec.)
Expression
Inc., p = 0.005
Dec., p = 0.010
Dec., p = 0.000
Inc., p = 0.000
Inc., p = 0.005
Dec., p = 0.045
Dec., p = 0.023
Inc., p = 0.001
Inc., p = 3.94E-05
Inc., p = 0.000
Dec., p = 0.023
Inc., p = 0.032
Inc., p = 0.030
Dec., p = 0.009
Inc., p = 0.002
Dec., p = 0.000
Dec., p = 1.68E-07
Inc., p = 0.030
Inc., p = 8.64E-05
Inc., p = 0.000
Dec., p = 9.19E-07
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Table 4 cont.

Putative Wt1 Targets
AMPK pT172
beta-Catenin
cIAP
Cyclin B1
GSK3-alpha-beta pS21 S9
GSK3 pS9
HER2 pY1248
Notch1
p70S6K pT389
PI3K p85
PTEN
Rb pS807 S811
S6 pS235 S236
STAT3 pY705
STAT5-alpha
Syk
YAP

Increased (Inc.) vs. Decreased (Dec.)
Expression
Dec., p = 0.012
Dec., p = 0.006
Dec., p = 0.010
Inc., p = 0.024
Dec., p = 0.001
Dec., p = 0.004
Dec., p = 0.003
Inc., p = 0.006
Dec., p = 0.011
Dec., p = 0.012
Dec., p = 0.041
Dec., p = 0.039
Dec., p = 0.041
Dec., p = 0.050
Dec., p = 0.000
Inc., p = 0.029
Inc., p = 0.046
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Discussion:
One of the major focuses of this study is determining the functional
consequences of decreased PRKCα in the developing kidney and its contribution to
Wilms tumorigenesis. Because previous experiments discussed in Chapter 2
demonstrated that WT1 does, in fact, regulate PRKCα expression, it is important to
determine how this signaling pathway affects downstream expression of target genes. As
discussed, the ubiquitous nature of PRKCα expression complicates the identification of
its tissue and cellular specific roles. Therefore, in order to better understand how WT1
and PRKCα together affect kidney development, separate RPPA and PCR Array
experiments can be evaluated with the purpose of comparing results. Comparing gene
changes following WT1 knockdown to gene changes following PRKCα knockdown
should identify genes in common between the two groups. If WT1 and PRKCa are the
beginning of a signaling pathway important to kidney function and implicated in
tumorigenesis, affected gene signaling pathways can then be constructed to determine
biological consequences of decreased WT1/PRKCα expression.
In assessing the targets identified by Prkcα knockdown PCR Array alone, a few
important observations arise. First, many of the targets identified play important roles in
increased angiogenesis and proliferation, such as the differentially expressed Vegf genes
(Figure 13). VEGF is a major regulator of angiogenesis that can aberrantly bind and
activate downstream tyrosine kinase receptors to drive tumor formation in multiple
cancer models (Lee, Dublin, Bobrow, & Poulsom, 1998; Salven et al., 1998; Takahashi,
Kitadai, Bucana, Cleary, & Ellis, 1995). Interestingly, experiments at the RNA level
show that VEGF expression is increased in our system following knockdown of PRKCα.
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Additionally, other differentially expressed targets were identified, such as: Thbs1, Tgfb,
and Itga2. The role of Itga2 in cellular remodeling and angiogenesis is well defined
(Grzesiak & Bouvet, 2006; Ruosiahti, 1991) and some studies also implicate Thbs1 and
Tgfb as cofactors involved in tumor cell attachment and invasion (Albo et al., 1994).
Overall, the majority of the PRKCα targets identified by PCR Array and listed in Figure
13 are known to act within the signaling pathways affecting cellular growth, with many
of the involved in increased angiogenesis and proliferation, increased vascular
permeability, and inhibited apoptosis (Doerks, Copley, Schultz, Ponting, & Bork, 2002).
Interestingly, and as predicted by our hypothesis, the Wt1 knockdown PCR Array
identified some of the same targets as those identified in the Prkcα knockdown PCR
Array. Both arrays show the Vegf family to be differentially expressed at the RNA level;
it is likely that signaling through these genes, mutant WT1 eventually leads to increased
angiogenesis in the developing kidney - possibly contributing to tumorigenesis (Dohi et
al., 2010; Ozluk, Kilicaslan, Gulluoglu, Ayan, & Uysal, 2006; Skoldenberg et al., 2001).
A full list of gene changes identified by Wt1 knockdown PCR Array can be found in
Figure 12 for comparison.
Further insight into the downstream effects of WT1 and PRKCα is revealed
through analysis of protein changes following the knockdown and up-regulation of the
two genes in RPPA experiments. High-throughput RPPA experiments identified a
number of protein targets differentially expressed following knockdown of either Wt1 or
Prkcα in the mouse mesenchymal cell line M15 (Table 4) or induced expression of WT1
in human embryonic cell line HEK293 (Table 3). Much like PCR Array data, a number
of the genes identified are involved in known cancer pathways. Results of protein
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analysis are best visualized in heatmap representations (Figure 14) and show a number
of expression changes. Notably, knockdown of Prkcα identified disregulation of genes
involved in insuling signaling, MAPK/Erk, and mTOR pathways – all of which are
hypothesized to contribute to increased cell growth, increased protein synthesis, and
increased proliferation.
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Chapter 5: Investigating the relationship between WT1 mutations and
PRKCα expression in Acute Myeloid Leukemia
Introduction:
Apart from Wilms tumor, WT1 also plays an important role in Acute Myeloid
Leukemia (AML) disease progression. WT1 mutations occur at a frequency of
approximately 10% and cluster to exons seven and nine in cytogenetically normal
patients (King-Underwood et al., 1996). WT1 mutation status has been implicated,
controversially, as an independent poor-prognosis factor in leukemia, leading to
decreased probability of overall survival, complete remission, and disease free survival
(King-Underwood & Pritchard-Jones, 1998; Paschka et al., 2008). RPPA analysis of
AML patient samples showed similar decreases in PRKCα/p-PRKCα protein expression
as seen in the human Wilms tumor heatmap (Dr. Steven Kornblau, Department of
Leukemia, The University of Texas MD Anderson Cancer Center, personal
communication). Therefore, the possible role of WT1 and PRKCα in leukemia disease
progression is an additional focus of this study.
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Materials/Methods:
Mutation Analysis:
Mutation analysis was carried out on 54 diploid AML leukemia patient samples,
chosen based upon high or low PRKCα and p-PRKCα S657 expression levels, to
identify patients harboring WT1 mutations. Patient DNA samples were obtained from
Dr. Steven Kornblau (Department of Leukemia, The University of Texas MD Anderson
Cancer Center) and given unique identification codes to create an unbiased test
environment during mutation analysis. Amplification of WT1 exons one through ten
were carried out using primer sets and PCR conditions listed in Table 4. PCR products
were analyzed by Sanger-based sequencing at the MD Anderson Cancer Center
Department of Genetics, Sequencing and Microarray Facility, followed by qPCR
validation of results and assessment for loss of heterozygosity.

Creation of Cell lines:
HL60 (human promyelocytic cells) cell lines were transduced using lentirviral
delivered shRNA. Two separate MISSION TRC shRNA Custom Lentiviral Particles,
pLKO-puro-IPTG-3xLacO, targeting WT1 and PRKCα were used (Sigma-Aldrich), as
well as lentivirus carrying non-target sequence negative control (NTC) shRNA. In 48
well plates, 2.0x104 cells were seeded per well along with lentivirus at 20 MOI targeting
WT1, PRKCα, or NTC. Cells were incubated in media containing Polybrene (Sigma) for
4hrs at 37 °C before 30min centrifugation followed by fresh virus application and
overnight incubation. Transduced cells were grown for an additional six days under
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puromycin selection to ensure uptake of viral construct selection of colonies for HL60WT1-shRNA, HL60-PRKCα-shRNA, and HL60-NTC-shRNA cell lines.

shRNA Knockdown:
qPCR analysis confirmed knockdown of appropriate gene targets after 48hrs of
50uM ITPG induction.
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5’CGGTCAAAAGGGGTAGGAGA3’
5’TAGAGTGGAGTCGAGGCGTCT3’
5’AAGGAGGAAAGCGTTCTA3’
5’GTCCTAACTCCTGCATTG3’
5’TCAGACCCAGGGGACGAGCA3’
5’AACCTGGGTCCTTAGCAGT3’
5’GAATCATGAAATCAACCCTAGCC3’
5’AATCCCTCTCATCACAAT3’
5’GGCCTGTGAGTCAACTAA3’

5’CGCCGGTGCTGGACTTTG3’
5’CGTCTTCCTGCCGAAAGTC3’
5’ATCCCTTCTGTCGTGTATGAA3’
5’TTGAGGGGCTTTTCACTGG3’
5’GCATTTCCAAATGGCGACTG3’
5’CCCTCAAGACCTACGTGAATG3’
5’CCTAACAAGCTCCAGCGAAGT3’
5’GGACTGGGGAAATCTAAG3’
5’GGGTGCCTTGTGATGACTTC3’

3’ Exon 1

Exon 2 & 3

Exon 4

Exon 5

Exon 6

Exon 7

Exon 8

Exon 9

Exon 10

Exon 4 -10: 95 °C - 3 min, [94 °C - 30 sec, 55 °C - 30 sec, 72 °C - 30 sec] - 40 cycles, 72 °C - 3 min

Exon 2 & 3: 95 °C - 3 min, [95 °C - 30 sec, 62 °C - 30 sec, 72 °C – 1 min 30 sec] - 40 cycles, 72 °C - 5 min

3’ Exon 1: 95 °C - 3 min, [95 °C - 30 sec, 62 °C - 30 sec, 72 °C - 30 sec] - 40 cycles, 72 °C - 3 min

5’ Exon 1: 95 °C - 3 min, [94 °C - 30 sec, 61 °C - 30 sec, 72 °C - 30 sec] - 40 cycles, 72 °C - 3 min

5’AACGACCCGTAAGCCGAAGC3’

5’AGCCAGAGCAGCAGGGAGTC3’

5’ Exon 1

Reverse Primer

Forward Primer

Detected

Cycle Conditions:

Table 5

429bps

320bps

282bps

303bps

317bps

225bps

425bps

979bps

432bps

277bps

Product Size

Results:
WT1 mutation analysis of 54 diploid leukemia patient samples identified two
patients with mutations hypothesized to lead to a mutant WT1 protein. Patient 1 has a
homozygous frameshift deletion, c. 939delG, in exon 7 identified by sanger-based
sequencing and analyzed using Mutation surveyor software. The frameshift mutation
results in 67 novel amino acids before reaching a stop codon. Patient 2 was identified to
with a heterozygous point mutation at the exon 8 splice site, c.1046-1G>A (Figure 15).
The overall frequency of WT1 mutations in our cohort was 2/54 or 3.7%. However,
considering cytogenetically normal patients alone, the frequency of mutations is 2/23 or
8.6%.
qPCR analysis of lysates from HL60-WT1-shRNA, HL60-PRKCα-shRNA, and
HL60-NTC-shRNA cell lines induced for shRNA expression for 48hrs confirmed
knockdown of target proteins (Figure 16). 70% knockdown of PRKCa was achieved in
cell line HL60-PRKCα-shRNA and 67% knockdown of WT1 was achieved in HL60WT1-shRNA cell line. Additionally, qPCR analysis showed that following the 67%
knockdown of WT1 in HL60-WT1-shRNA, a 60% decrease in PRKCα was observed.
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(a)
(a)

(b)

Figure 15: (a) Patient 1 has a homozygous deletion in exon 7. The frameshift mutation
results in 67 novel amino acids before a stop codon is reached; 70 amino acids shorter
than the wild type WT1 protein. (b) Patient 2 has heterozygous point mutation at the
exon 8 splice site; and is predicted to results in a mutant WT1 protein.
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1.00
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NTC siRNA
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1.01 1.13

0.20

0.00

1.60

0.80Control
0.60HL60
1.00 1.10
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1.20

*
*
0.36

0.00
WT1
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Un-Induced
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*

0.60
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0.91

0.40
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NTC
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Control
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0.72

0.91
0.52
0.33

0.00
WT1

PRKCa

Figure 16: (a) No significant changes in WT1 or PRKCα RNA expression were seen
following induction of non-target control shRNA in HL60 cell culture. (b) No changes
in RNA expression were seen after treating control HL60 cells with IPTG. (c) Following
48hrs of induced shRNA expression in HL60-WT1-shRNA cell culture, a significant
decrease in WT1 (p=0.0396) and PRKCα (p=0.0421) RNA expression was observed. (d)
Following 48hrs of induced shRNA expression in HL60-PRKCα-shRNA cell culture, a
significant decrease in PRKCα RNA expression (p=0.023) was observed.
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Discussion:
According to our hypothesis, a mutation analysis of 54 leukemia patient samples
should reveal that patients harboring a WT1 mutation also have decreased PRKCα
expression. We predict the frameshift mutation identified in Patient 1 would produce a
nonfunctional, mutant WT1 protein a full 70 amino acids shorter than the wild type
protein, resulting in a truncated protein lacking correct formation of the four zinc fingers
that allow WT1’s DNA binding ability. While we can be sure that the first patient, with a
frameshift mutation, does in fact express a non-functional WT1 protein, the same is not
definitive for the second patient whose mutation occurs at the exon 8 splice site. We
only predict that a mutation at this location results in a truncated WT1 protein.
Correlating the WT1 mutation status of the two patients with protein expression
levels, we would expect both to have low PRKCα expression. Interestingly, Patient 1
does in fact express very low levels of PRKCα, but Patient 2 does not have low PRKCα
expression. One possible explanation for the high level of PRKCα expression in Patient
2 is that the mutation does not affect WT1 function; instead, the patient has a normally
functioning WT1 protein product and so we would not expect decreased PRKCα
expression, but without further experimentation we cannot conclude this definitively.
Lentiviral constructs applied to the HL60 cell line achieved significant
knockdown of targets. HL60-WT1-shRNA cells showed a significant decrease in WT1
RNA expression and a resulting significant decrease in PRKCα expression. Once again,
we would expect to see this decrease in PRKCα expression following WT1 knockdown.
HL60-PRKCα-shRNA cells also achieved knockdown of the target gene, with a
significant decrease in PRKCα expression (and no significant change in WT1
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expression). Altogether, these results confirm the hypothesis that WT1 is regulation
PRKCα expression; and in leukemia patients, the observed decrease in PRKCα
expression can possibly be attributed to mutant WT1 expression.
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IMPLICATIONS
The research I presented in this Thesis identifies PRKCα as a novel target of
WT1 transcription factor. By first identifying the temporal and spatial expression of
PRKCα, I was able to confirm its expression in embryonic kidney at a timepoint
important to kidney development. Importantly, I showed that it is co-expressed in
mesenchymal cells with WT1 transcription factor during the mesenchymal to epithelial
transition – cell from which Wilms tumors are hypothesized to arise. Various in-vitro
systems confirmed the observation originally made in human patient protein expression
data that patients harboring WT1 mutations have significantly decreased PRKCα
expression. Both knockdown and up-regulation experiments showed that manipulating
WT1 expression resulted in similar changes in PRKCα expression. Biological
significance was achieved by also being able to show decreased PRKCα expression in
the embryonic kidney of WT1 conditional knockout mice.
Another focus of this study was determining the functional consequences of
decreased PRKCα and its potential contribution to Wilms tumorigenesis. The
downstream targets of WT1 transcription factor are largely unidentified and efforts are
being made to better characterize the consequences of mutant protein expression on
signaling pathways. This works has identified PRKCα as a target of WT1 transcriptional
activity and elucidated the consequences of disrupted signaling following decreased
PRKCα expression. High-throughput experiments identified a wide variety of putative
targets downstream of the aberrant expression of PRKCα, many of which play a role in
cell-growth and proliferation. Known cancer pathways contributing to angiogenesis,
protein synthesis, and cell proliferation are all identified here as aberrantly expressed and
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point to the implication of mutant WT1 – decreased PRKCα signaling pathway in Wilms
tumorigenesis. I predict that continued investigation into the role of PRKCα in the
developing kidney and its potential contribution to Wilms tumorigenesis will offer
interesting insight into disease etiology. Additionally, high-throughput WT1 knockdown
and up-regulation experiments can be evaluated independently in order to identify new
targets of WT1 transcription factor, independent of PRKCα signaling, that may play a
role in tumor formation.
Furthermore, this Thesis has addressed the relationship between WT1 and
PRKCα in Acute Myeloid Leukemia Patients. The role of the WT1 transcription factor in
leukemia is particularly interesting in that it may serve as a novel predictor of disease
outcome. Research has indicated that by assessing for WT1 expression, a determination
of the probability of OS and DFS of patients can be made. Here I have confirmed that in
the developing kidney, WT1 is regulating PRKCα, directly or indirectly. The importance
of this investigation is obvious in its implications to patient survival and treatment. I was
able to identify at least one patient whose WT1 mutation is associated with decreased
PRKCα - who later suffered disease relapse. It is my opinion that future investigations
will identify WT1 mutation status and PRKCα expression levels as important drivers in
acute myeloid leukemia disease.
Through my research I have provided new insight into the role of WT1 and its
regulation of PRKCα either directly or indirectly. Identification of a novel target of WT1
transcription factor provides not only a new avenue for future studies on kidney
development and Wilms tumorigenesis but other diseases as well. Ongoing research into
the role of WT1 has implicated the transcription factor as an important regulator in a
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wide variety of tissues and diseases, and this observation, combined with the ubiquitous
expression of PRKCα offers great potential for the importance of WT1 – PRKCα
signaling in human disease.
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